Sorafenib-to-regorafenib sequence-induced atherosclerotic cardiovascular disease: a novel case report
{{output}}
This case report describes a 59-year-old male with HBV-associated hepatocellular carcinoma who developed progressive atherosclerotic cardiovascular disease (ASCVD) during sequential treatment with sorafenib and regorafenib. Initial sorafenib therapy (400 mg tw... ...
